Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 11/20 | 1.00 |
| ▸ | DRD2 | P14416 | 10/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.75 |
| ▸ | DRD4 | P21917 | 7/20 | 0.67 |
| ▸ | DRD1 | P21728 | 5/20 | 0.67 |
| ▸ | DRD5 | P21918 | 5/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | PRCP | P42785 | 1/20 | 0.65 |
| ▸ | EBP | Q15125 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873549 | 1.00 | DRD3 (1.00) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL29369425 | 1.00 | DRD3 (1.00) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL873812 | 1.00 | DRD3 (1.00) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| Hydrochloric Acid SCHEMBL5678691 | 0.99 | DRD3 (0.98) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| Hydrochloric Acid SCHEMBL5678697 | 0.99 | DRD3 (0.98) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| Bromide SCHEMBL7023734 | 0.99 | DRD3 (0.98) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| Bromide SCHEMBL5699015 | 0.99 | DRD3 (0.98) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| Hydrochloric Acid SCHEMBL29634866 | 0.99 | DRD3 (0.98) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL6880380 | 0.92 | DRD3 (0.84) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL6881711 | 0.92 | DRD3 (0.84) | DRD3DRD2SIGMAR1DRD4DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3294337-B1 | TREATMENT OF DEBILITATING FATIGUE BY COMBINED USE OF 3(S)-3-[3-(METHYLSULFONYL)PHENYL]-1- PROPYLPIPERIDINE AND AN ANTI-DEPRESSIVE AGENT | ARVID CARLSSON RES AB (SE) | 2024-12-18 | — | — | EP | claimed |
| US-20210106570-A1 | Treatment of Debilitating Fatigue | ARVID CARLSSON RESEARCH AB (SE) | 2021-04-15 | — | — | US | claimed |
| US-10702512-B2 | Treatment of debilitating fatigue | A. CARLSSON RESEARCH AB (SE) | 2020-07-07 | — | — | US | claimed |
| US-20180169081-A1 | Treatment of Debilitating Fatigue | A CARLSSON RES AB (SE) | 2018-06-21 | — | — | US | claimed |
| EP-3294337-A1 | TREATMENT OF DEBILITATING FATIGUE | A.Carlsson Research AB (SE) | 2018-03-21 | — | — | EP | claimed |
| WO-2016180879-A1 | TREATMENT OF DEBILITATING FATIGUE | A. CARLSSON RESEARCH AB (SE) | 2016-11-17 | — | — | WO | claimed |
| EP-2618826-B1 | PHENYLPIPERIDINE COMPOUNDS FOR THE TREATMENT OF DEMENTIA | CARLSSON A RESEARCH AB (SE) | 2016-04-13 | — | — | EP | claimed |
| EP-2170327-B1 | USE OF DOPAMINE STABILIZERS | CARLSSON A RESEARCH AB (SE) | 2014-10-22 | — | — | EP | claimed |
| US-20130197032-A1 | PHENYLPIPERIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | A. CARLSSON RESEARCH AB (SE) | 2013-08-01 | — | — | US | claimed |
| EP-2618826-A1 | PHENYLPIPERIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | A.Carlsson Research AB (SE) | 2013-07-31 | — | — | EP | claimed |
| US-20040228915-A1 | Oral extended release compressed tablets of multiparticulates | NOACK ROBERT M (US) | 2004-11-18 | — | — | US | claimed |
| WO-2004087175-A1 | ORAL EXTENDED RELEASE COMPRESSED TABLETS OF MULTIPARTICULATES | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | claimed |
| EP-1455751-A1 | ZERO-ORDER SUSTAINED RELEASED DOSAGE FORMS AND METHOD OF MAKING THE SAME | Pharmacia Corporation (US) | 2004-09-15 | — | — | EP | claimed |
| EP-1335721-A2 | METHOD OF TREATING AND PREVENTING MIGRAINE HEADACHES | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-20 | — | — | EP | claimed |
| US-20030133982-A1 | Zero-order sustained release dosage forms and method of making same | PHARMACIA CORPORATION | 2003-07-17 | — | — | US | claimed |
| US-6589965-B2 | Using substituted phenylazacycloalkanes. | PHARMACIA & UPJOHN COMPANY | 2003-07-08 | — | — | US | claimed |
| WO-2003053402-A1 | ZERO-ORDER SUSTAINED RELEASED DOSAGE FORMS AND METHOD OF MAKING THE SAME | PHARMACIA CORPORATION (US) | 2003-07-03 | — | — | WO | claimed |
| US-20020091140-A1 | Method of treating and preventing migraine headaches | PHARMACIA & UPJOHN COMPANY | 2002-07-11 | — | — | US | claimed |
| WO-2002036071-A2 | METHOD OF TREATING AND PREVENTING MIGRAINE HEADACHES | PHARMACIA & UPJOHN COMPANY (US) | 2002-05-10 | — | — | WO | claimed |
| EP-0641320-B1 | SUBSTITUTED (S)-3-PHENYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE AUTORECEPTOR ANTAGONISTS | UPJOHN CO (US) | 2001-05-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091140-A1 | Method of treating and preventing migraine headaches | PDE2A, PDE3A, HNMT | DRD3 3007/4885DRD2 3426/4885SIGMAR1 1924/4885 |
| US-20180169081-A1 | Treatment of Debilitating Fatigue | COMT, MYOF, NEFM | DRD3 169/4885DRD2 119/4885SIGMAR1 532/4885 |
| US-10702512-B2 | Treatment of debilitating fatigue | COMT, MYOF, NEFM | DRD3 169/4885DRD2 119/4885SIGMAR1 532/4885 |
| US-20130197032-A1 | PHENYLPIPERIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | HTR5A, HTR2A, HTR1A | DRD3 186/4885DRD2 36/4885SIGMAR1 121/4885 |
| US-20210106570-A1 | Treatment of Debilitating Fatigue | COMT, MYOF, NEFM | DRD3 169/4885DRD2 119/4885SIGMAR1 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.